115279-73-7

Usage

Uses

Given the limited information on ASISCHEM D50964, it is challenging to list specific applications without accurate details from the manufacturer or supplier. However, if it is identified as a chemical with specific properties or functions, potential uses could be explored in various industries, such as pharmaceuticals, cosmetics, food and beverage, or industrial manufacturing. The applications would depend on the chemical's properties, safety profile, and regulatory approval for use in specific contexts.
Used in Pharmaceutical Industry:
If ASISCHEM D50964 is identified as a chemical with therapeutic properties, it could be used as an active pharmaceutical ingredient for [specific medical condition or treatment purpose].
Used in Cosmetics Industry:
If ASISCHEM D50964 is found to have properties suitable for cosmetic products, it could be used as an ingredient in skincare or haircare products for [specific cosmetic purpose, such as moisturizing or conditioning].
Used in Food and Beverage Industry:
If ASISCHEM D50964 is approved for use in food and beverages, it could be used as a [preservative, flavor enhancer, or other food additive purpose] to improve the quality, taste, or shelf life of products.
Used in Industrial Manufacturing:
If ASISCHEM D50964 has specific properties applicable to industrial processes, it could be used as a [catalyst, solvent, or other industrial chemical purpose] to enhance manufacturing processes or product performance.

InChI:InChI=1/C12H14N2/c13-9-12(7-1-2-8-12)10-3-5-11(14)6-4-10/h3-6H,1-2,7-8,14H2

Upstream product

• 91392-33-5 1-(4-nitrophenyl)cyclopentane-1-carbonitrile 
• 77-57-6 1-phenyl-1-cyclopentanecarbonitrile 
• 140-29-4 phenylacetonitrile 
• 555-21-5 4-Nitrophenylacetonitrile 

Downstream Products

• 133825-88-4 1-<4-(dimethylamino)phenyl>cyclopenatnecarbonitrile 
• 1030545-24-4 2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid [4-(1-cyano-cyclopentyl)-phenyl]-amide 
• 91640-63-0 1-(p-aminophenyl)cyclopentanecarboxylic acid 
• 1067189-46-1 N-[4-(1-cyano-cyclopentyl)-phenyl]-4-dimethylamino-benzamide 
• 1030658-42-4 benzo[1,3]dioxole-5-carboxylic acid [4-(1-cyano-cyclopentyl)-phenyl]-amide 
• 1067189-51-8 N-[4-(1-cyano-cyclopentyl)-phenyl]-4-hydroxy-3-methoxy-benzamide 
• 1067189-54-1 3,4-dimethoxy-N-{4-[1-(5-methyl-[1,2,4]oxadiazol-3-yl)-cyclopentyl]-phenyl}-benzamide 
• 1275609-09-0 N-[4-(1-cyanocyclopentyl)phenyl][2-[(4-pyridylmethyl)amino](3-pyridyl)]carboxamide 
• 1158560-99-6 N-[4-(1-cyanocyclopentyl)phenyl][2-chloro(3-pyridyl)]carboxamide 
• 1067189-50-7 3,4-dimethoxy-N-[4-(1-methylcarbamoyl-cyclopentyl)-phenyl]-benzamide 
• 1067192-35-1 1-[4-(3,4-dimethoxy-benzoylamino)-phenyl]-cyclopentanecarboxylic acid 
• 1067189-49-4 1-[4-(3,4-dimethoxy-benzoylamino)-phenyl]-cyclopentanecarboxylic acid methyl ester 

Relevant academic research and scientific papers

Industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles-catalyzed hydrogenation of nitroarenes

The development of green and efficient methods for hydrogenation of nitroarenes is still highly demanding in organic synthesis. Herein, we report an industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles process for the synthesis of aryl amines with good yields via hydrogenation of nitroarenes. Nine key anti-cancer drug intermediates were successfully achieved with protocol. And Osimertinib intermediate 4m can be smoothly synthesized at a 2.67 kg-scale with >99.5% HPLC purity. This protocol features cheap carbon source, highly catalytic activity, simple operation, kilogram-scalable and recyclable catalysts (eight times without observable losing activity).

CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES

A chemoselective and reactive Mn(CF3-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic C—H hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.

Apatinib preparation method

The present invention relates to an apatinib preparation method, wherein specifically an organic solvent is selected to perform refining crystallization to obtain the apatinib. The method of the present invention has advantages of simple operation and low cost, and is suitable for large-scale production.

SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO

A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE

The present invention provides new compounds of formula I, wherein Q, R1, R2, R4, R5, R6, Xi, R7, R8, M and G1 nare defined as in formula I; invention compounds are modulators of follicle-stimulating hormone - ("FSH") which are useful for male and female contraception as well as other disorders modulated by FSH receptor.

Inhibitors of Acyl-CoA: Cholesterol Acyltransferase (ACAT). 7. Development of a Series of Substituted N-Phenyl-N'-ureas with Enhanced Hypocholesterolemic Activity

We recently described our initial structure-activity relationship (SAR) studies on a series of N-phenyl-N'-aralkyl- and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT).From this series of analogs, compou